Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



This Obesity Biotech Is Going Mobile

Mobile devices today have become ubiquitous, and tech companies are not the only ones trying to profit from this trend. Drugmakers have also started to catch on to the power of marketing through smartphones. Sanofi (NYSE: SNY  ) , a leading provider of long-acting diabetes medications, was one of the first movers in this space and has a blood glucose monitor that works with iPhones.

Today, obesity drugmaker VIVUS (NASDAQ: VVUS  ) announced that it is also getting in on this emerging trend. In an effort to further entice patients to try its obesity medication, Qsymia, VIVUS has announced a new mobile app that can help patients comply with their treatment. Health care analyst Max Macaluso discusses this story -- and what it means for investors -- in the following video.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2300178, ~/Articles/ArticleHandler.aspx, 11/28/2015 3:18:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Max Macaluso

Max is the Technology, Biopharma & Health Care Bureau Chief at Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Today's Market

updated 20 hours ago Sponsored by:
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 1.24 0.06%
NASD 5,127.53 11.38 0.22%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/27/2015 12:59 PM
VVUS $1.38 Up +0.02 +1.47%
VIVUS, Inc. CAPS Rating: ***
SNY $44.31 Up +0.06 +0.14%
Sanofi (ADR) CAPS Rating: ****